Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Polyclonal immunoglobulin G antibodies are a heterogeneous mixture of antibodies produced by different B cell lineages in response to an antigen. Each antibody recognizes a different epitope on the same antigen, resulting in broad specificity and enhanced sensitivity for detecting or neutralizing targets. In clinical medicine, polyclonal IgG preparations—such as anti-thymocyte globulin—are used primarily for immunosuppression in organ transplantation and treatment of certain blood disorders like aplastic anemia. These products work by targeting various immune system proteins on lymphocytes and other cells, thereby suppressing immune responses[3][4]. While highly effective due to their broad reactivity, they can also cause side effects such as allergic reactions.
Broad antigen binding to multiple epitopes, leading to immune modulation or suppression[3][4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin G (IgG) polyclonal antibody (IgG pAb).